Dare Bioscience, Inc. (DARE) company profile
Close on Nov 13, 2026Market cap $10.05MP/E –Yield –
About Dare Bioscience
Pharmaceutical Preparations, SIC 2834
Daré Bioscience, Inc. is a biopharmaceutical company that develops and commercializes health products specifically designed for women. The company targets therapeutic areas including contraception, sexual health, vaginal health, pelvic pain, fertility, and menopause. Its commercial portfolio features XACIATO, an FDA-approved prescription vaginal gel licensed to Organon for treating bacterial vaginosis, as well as DARE to PLAY Sildenafil Cream, which is compounded under Section 503B regulations for female sexual arousal disorder. Additionally, Daré offers non-prescription consumer wellness items, including Flora Sync LF5 under the DARE to RESTORE vaginal probiotic line. The company serves female patients, healthcare providers, and consumers through telehealth services, dispensing pharmacies, and commercial partners.
The company operates primarily within the United States, utilizing third-party manufacturing facilities, pharmacy distributors, and clinical trial sites across the country. Daré Bioscience maintains no internal sales, distribution, or marketing infrastructure, relying instead on strategic commercial collaborators and registered outsourcing facilities. The provided excerpt does not disclose the location of the company's corporate headquarters.
Summary of the business section of Dare Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Dare Bioscience, Inc.
- Headquarters
- San Diego, CA
- Address
- 3655 Nobel Drive, Suite 260 92122
- Phone
- (858) 926-7655
- Website
- darebioscience.com
- Employees
- 24, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- DARE
- Former tickers
- CERU until Aug 14, 2017
- Exchange
- Nasdaq
- IPO date
- Apr 14, 2014
- Shares outstanding
- 15M, Aug 12, 2026
- Public float
- $21.34M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Jul 1, 2024; 1-for-10 reverse, Jul 20, 2017
- SEC CIK
- 1401914
- CUSIP
- 23666P200
- ISIN
- US23666P2002
- FIGI
- BBG001J2P362
- Share class FIGI
- BBG001V0GDP9
- EIN
- 20-4139823
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sabrina Martucci Johnson | Chef Executive Officer, Director | 962,062 |
| MarDee Haring-Layton | Chief Accounting Officer | – |
| Jessica D. Grossman | Director | 26,066 |
| Susan L. Kelley | Director | 23,696 |
| Robin Joan Steele | Director | 293,226 |
| William H. Rastetter | Director | 100,028 |
| Gregory W. Matz | Director | 31,347 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $801.08K | $585.89K | $546.86K | $19 | – |
| FY2024 | $898.38K | $754.03K | $455.77K | $31 | – |
| FY2023 | $1.22M | $450.42K | $751.59K | $37 | – |
| FY2022 | $1.67M | $594.24K | $777.54K | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 14, 2014
- Offer price
- $7.00
- Securities offered
- 8,500,000
- Gross proceeds
- $59.50M
- Exchange
- Nasdaq
- First trading day
- Apr 11, 2014
- First-day close
- $6.85-2.1%
- Lock-up ends (est.)
- Oct 8, 2014
“Per Share Total Initial public offering price $ 7.00 $ 59,500,000 Underwriting discount on shares offered to the public(1) $ 0.49 $ 2,149,546 Underwriting discount on shares offered to certain of our existing stockholders(1) $ 0.31 $ 1,259,865 Proceeds, before expenses, to us $ 6.60 $ 56,090,590 (1) We have agreed”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 25, 2026, we had 24 employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?